Highly sensitive detection of circulating tumour cells based on an ASV/CV dual-signal electrochemical strategy

Circulating tumour cells (CTCs), as a tumour marker, may provide more information in early diagnosis and accurate therapy of cancer patients. Electrochemical detection of CTCs has exhibited exceptional advantages. However, single-signal electrochemical detection usually has a high probability of false positives coming from interferents, operating personnel, and nonstandard analytical processes. Herein, a dual-signal strategy using anodic stripping voltammetry (ASV) and cyclic voltammetry (CV) for highly sensitive detection of CTCs was developed. When MCF-7 cells were present, aptamer DNA (DNA1)-magnetic beads (MBs) were captured by CTCs and detached from the biosensing electrodes. Following magnetic separation, polystyrene bead (PS)-CdS QDs labelled on MCF-7 cells were dissolved by HNO3 and the intensity of the oxidation peak current of Cd2+ ions was proportional to the amount of MCF-7 cells in ASV (y = 6.8929 lg Ccells + 1.0357 (Ccells, cells per mL; R2, 0.9947; LOD, 3 cells per mL)). Meanwhile, the anodic peak currents of the remaining electrode in CV were also proportional to the amount of MCF-7 cells (y = 3.7891 lg Ccells + 52.3658 (Ccells, cells per mL; R2, 0.9846; LOD, 3 cells per mL)). An ASV/CV dual-signal biosensor for electrochemical detection of CTCs was achieved, which overcame the limitations of any single-signal mode and improved the detection reliability and precision. Highly sensitive electrochemical detection of circulating tumour cells using a dual-signal strategy.

Automated summary

This study developed a dual-signal strategy using anodic stripping voltammetry (ASV) and cyclic voltammetry (CV) for highly sensitive detection of circulating tumour cells (CTCs). The dual-signal biosensor overcame the limitations of any single-signal mode and improved the detection reliability and precision.